Wells Fargo lowered the firm’s price target on Crispr Therapeutics to $65 from $70 and keeps an Equal Weight rating on the shares following quarterly results. The firm continues to see the key focuses going forward for Crispr as the Casgevy launch in SCD/TDT, allo-CAR T in autoimmunity, and in vivo pipeline expansion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
- Crispr Therapeutics management to meet with Mizuho
- CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
- CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
- Crispr Therapeutics call volume above normal and directionally bullish